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Abstract
Background: Osteosarcoma is the most common primary malignant bone tumour in children and
young adults. Despite advances in the diagnosis and management of osteosarcoma, there have been
few recent studies describing the experiences of tertiary referral centres. This paper aims to
describe and discuss the clinical features, pre-operative work-up, management and outcomes of
these patients at St Vincent's Hospital (Melbourne, Australia).
Methods: Retrospective study of fifty-nine consecutive patients managed for osteosarcoma at St
Vincent's Hospital between 1995 and 2005.
Results: Median age at diagnosis was 21 (range, 11–84) years. Gender distribution was similar, with
thirty-one male and twenty-eight female patients.
Twenty-five patients had osteosarcoma in the femur, eleven each were located in the humerus and
tibia, six were identified in the pelvis, and one each in the clavicle, maxilla, fibula, sacrum, ulna and
radius.
Pre-operative tissue diagnosis of osteosarcoma was obtained through computed tomography-
guided percutaneous biopsy in over ninety percent of patients.
Following initial therapy, over fifty percent of patients remained relapse-free during the follow-up
period, with twelve percent and twenty-seven percent of patients documented as having local and
distant disease recurrence, respectively. Of patients with recurrent disease, sixty-two percent
remained disease-free following subsequent surgical intervention (most commonly, pulmonary
metastatectomy).
Conclusion: Patient outcomes can be optimised through a multidisciplinary approach in a tertiary
referral centre. At St Vincent's Hospital, survival and relapse rates of patients managed for
osteosarcoma compare favourably with the published literature.
Published: 03 November 2006
International Seminars in Surgical Oncology 2006, 3:38 doi:10.1186/1477-7800-3-38
Received: 19 October 2006
Accepted: 03 November 2006
This article is available from: http://www.issoonline.com/content/3/1/38
© 2006 Tan et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.International Seminars in Surgical Oncology 2006, 3:38 http://www.issoonline.com/content/3/1/38
Page 2 of 8
(page number not for citation purposes)
Background
Osteosarcoma is the most common primary bone malig-
nancy in children and young adults [1-5], typically pre-
senting with symptoms of pain or swelling. Older adults
may also be affected, usually as a result of sarcomatous
transformation of Paget's disease of bone [1-3,6]. Histo-
logically, osteosarcomas are highly aggressive spindle cell
neoplasms that produce osteoid. Overall, this malignancy
is rare, with an annual incidence of approximately one per
100,000 persons [1-5].
Since the 1970s, when two-year survival rates were fifteen
to twenty percent [2], patient outcomes have significantly
improved following the introduction of effective multi-
agent chemotherapy regimens. In addition, developments
in imaging techniques have contributed to more effective
management of osteosarcoma. These included computed
tomography (CT) and magnetic resonance (MR) evalua-
tion of bone and soft tissue involvement to facilitate sur-
gical planning, use of functional nuclear imaging and CT
chest for detection of metastatic disease, and imaging-
guided percutaneous biopsy to enable histopathological
diagnosis with minimal morbidity and complication
risks. Furthermore, advances in limb-salvage surgery and
reconstructive techniques in selected patients have ena-
bled preservation of limb function without compromis-
ing oncological outcomes [2,5].
A retrospective review of the experience at St Vincent's
Hospital with osteosarcoma was performed in order to
evaluate the diagnosis and management of these patients,
and the outcomes achieved.
Materials and methods
Between 1995 and 2005, fifty-nine consecutive patients
were diagnosed and managed for osteosarcoma at St Vin-
cent's Hospital, Melbourne, Australia. A retrospective
review of these patients was undertaken, with data on age
at diagnosis, gender, symptoms, site of the tumour, treat-
ment regimen, follow-up and outcomes, compiled from
the clinical notes, outpatient correspondences and his-
topathology reports.
Results
Age and gender
Median age at diagnosis was 21 (range, 11–84) years.
There were thirty-one male and twenty-eight female
patients.
Symptoms (see Figure 1)
Pain was the most common presenting symptom, being
the sole symptom in seventeen patients. Seven patients
presented with an asymptomatic mass lesion, eighteen
patients complained of a painful mass lesion, three
patients presented with a pathological fracture (two asso-
ciated with pain prior to diagnosis of fracture), two
patients experienced pain and limb weakness, and one
patient presented with bleeding. Four patients were found
to have metastatic disease at diagnosis. In the remaining
eleven patients, the presenting complaint was not speci-
fied.
Site of tumour (see Figure 2)
Twenty-five osteosarcomas were located in the femur; of
these, nineteen were in the distal femur, one in the proxi-
mal femur and in five the location was unspecified. Of the
other sites of tumour, eleven each were identified in the
humerus and tibia, and six in the pelvis. One case of oste-
osarcoma was diagnosed in each of the following loca-
tions: clavicle, maxilla, fibula, sacrum, ulna and radius.
Pre-operative diagnosis, treatment and outcome
Diagnosis and pre-operative assessment was performed
using a combination of plain radiographs, bone scan,
computed tomography scan (including of the chest),
magnetic resonance imaging and functional nuclear med-
icine including thallium scintigraphy and positron emis-
sion tomography (PET)-CT scan. In addition, imaging-
guided CT biopsy was performed in fifty-one patients; of
these, twenty-six were performed at St Vincent's Hospital
and twenty-five at external institutions. In five of these
patients, one of whom was initially biopsied outside St
Vincent's Hospital, open biopsy was required for defini-
tive diagnosis of osteosarcoma. In eight patients, pre-
sumptive diagnosis of osteosarcoma was made pre-
operatively and confirmed by histopathology following
surgical resection.
Fifty-five patients were managed with surgical resection,
including thirty patients who underwent limb-salvage sur-
gery with reconstruction. All but five patients received
chemotherapy; of patients who were administered chem-
otherapy, thirty-four patients received both neo-adjuvant
and adjuvant treatment, eighteen patients had only neo-
adjuvant and two patients had only adjuvant chemother-
apy. Three patients received radiotherapy, one as pallia-
tive management.
Median duration of follow-up, defined as the time from
diagnosis to that of the most recent clinical evaluation,
was twenty-eight (range, 1–111) months. Forty-five
patients were disease-free at the most recent follow-up
(see Figure 3). During the follow-up period, eleven
patients had died; of these, only one death was unrelated
to osteosarcoma. Twenty-one patients were found to have
had recurrent disease – in five patients there was local
recurrence, fourteen patients had metastatic disease and
two patients had both local recurrence and metastatic dis-
ease. Of the patients with known sites of metastatic dis-International Seminars in Surgical Oncology 2006, 3:38 http://www.issoonline.com/content/3/1/38
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ease, five had single metastases while eleven had multiple
metastases.
Discussion
Osteosarcoma is the most common primary bone malig-
nancy in children and adolescents, with an overall inci-
dence of approximately one per 100,000 per year [1-5].
Whilst most osteosarcomas are de novo tumours of
unknown aetiology, secondary causes include ionising
radiation, hereditary retinoblastoma, Paget's disease of
bone, enchondromatosis, hereditary multiple exostoses
and fibrous dysplasia [1-3,6].
Osteosarcoma typically presents between five and thirty
years of age [5], although a bimodal age distribution has
been noted, with a first peak at ten to twenty years of age
and a second peak in older adults aged in the fifth and
sixth decades of life [2]. The age of the patients in our
study were aged between eleven and eighty-four years, of
whom sixty-eight percent (n = 40) at diagnosis were aged
ten to thirty years inclusive.
As previously reported, there was no significant gender
preponderance in patients affected by osteosarcoma in
this study [1,3], although the incidence has been
described as being more frequent in males (1.5:1) [2,7].
Patients typically present with pain or swelling in a bone
or joint, and occasionally a pathologic fracture secondary
to marked weakening of bone at the site of the lesion,
which may occur on the background of minor trauma or
vigorous physical exercise [1,4-6]. Symptoms may be
present for several months (on average, three to four
months, but often exceeding six months) before a diagno-
sis is made [2-4,8]. Most patients present with localised
disease – eighty percent of these tumours are non-meta-
static at time of presentation [2,3,5]. In this series, only
seven percent of patients presented with metastatic dis-
ease. Osteosarcoma most commonly metastasises to lung
(ninety percent) and bone (ten percent) [1,7]. In patients
treated with surgical resection and/or radiotherapy with-
out chemotherapy, approximately eighty percent with
localised disease at presentation developed secondary dis-
ease related to micrometastases [2].
Osteosarcomas can occur in any bone but most com-
monly affects the metaphysis of long bones in the appen-
dicular skeleton (eighty percent) [7]. The most common
sites affected are: distal femur (thirty-five percent), proxi-
mal tibia (twenty percent), and proximal humerus (ten
percent) [1-3,5,7]; consistent with previous studies, over
half (sixty-one percent, n = 36) of osteosarcomas diag-
nosed in this study originated from the knee area [1,7].
Osteosarcoma can also affect the axial skeleton, although
this occurs in less than ten percent of the paediatric age
group; in these patients, the pelvis is most common site
[2]. Ten percent of osteosarcomas present in the head and
neck region, of which the average age of presentation is
Presenting symptoms Figure 1
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between the third and fourth decades [4]; only one patient
in this series had maxillary osteosarcoma.
The diagnosis of osteosarcoma is based on the demonstra-
tion of typical radiographic findings (see Figure 4) in asso-
ciation with characteristic cytologic features.
1. Plain radiographs
On plain radiographs, osteosarcomas typically appear as
an ill-defined mixed sclerotic and lytic lesion arising in the
metaphyseal region of the involved bone, with destruc-
tion of the bony cortex, formation of a soft tissue mass,
and ossification [2,5,7]. Periosteal new bone formation
with elevation of the cortex may also be present, forming
the appearance of a Codman triangle [2,3,7].
2. CT
CT scanning of the affected bone is superior to MR imag-
ing for the assessment of new bone formation and cortical
changes. In addition, CT chest is mandatory for detection
Frequency and Location of Osteosarcoma Figure 2
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of pulmonary metastases, the presence of which affect
management and prognosis.
3. MR imaging
MR imaging, with T1- and T2-weighted and fat-sup-
pressed sequences, is superior to CT in assessing for skip
lesions (on longitudinal images) and the extent of bone
and soft tissue involvement (on axial images). In particu-
lar, the intra-osseous extent of tumour and its proximity
to muscle groups, subcutaneous fat, joints and neurovas-
cular structures [2,3,5] for surgical planning is determined
with the most specificity on T1-weighted sequences but
with the most sensitivity on short tau inversion recovery
sequences [8]. Dense sclerosis within neoplastic bone
gives a hypointense signal on all sequences, especially on
T2-weighted images, while tumour within the marrow
appears hypointense on T1-weighted images and hyperin-
tense on T2-weighted images [8]. MR axial T1-weighted
Patient Outcomes Figure 3
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fat-suppressed post-contrast images may be used to assess
tumour viability and response to neo-adjuvant chemo-
therapy prior to surgical resection [8].
4. Nuclear medicine
Functional nuclear imaging assesses the metabolic activity
of tumour.
Triple-phase whole-body scintigraphy is useful for detec-
tion of bone metastases. In instances where MR imaging is
unhelpful for monitoring tumour response to neo-adju-
vant chemotherapy and detection of local recurrence,
thallium scintigraphy may be performed.
PET-CT is emerging as a tool for non-invasive assessment
of neo-adjuvant chemotherapy response in osteosarcoma
[9-12], and may potentially have a role in post-treatment
follow-up detection of metastatic disease, although it has
been reported in small studies as being less sensitive than
bone scintigraphy and thoracic CT for detection of
osseous and pulmonary metastases, respectively [13,14].
Lack of access to this imaging modality also limits its cur-
rent use.
5. CT-guided biopsy
Although radiographic appearance and location of
tumour is predictive of osteosarcoma in two-thirds of
cases, pathologic confirmation by biopsy is more defini-
tive. Percutaneous biopsy is minimally invasive, requires
minimal wound healing, and is associated with a lower
risk of infection, contamination and post-biopsy fracture
[5]. In particular, core biopsies performed under local
anaesthaesia are capable of obtaining an adequate speci-
men with tissue architecture maintained, enabling diag-
nostic accuracy of over ninety-five percent [2]. In this
study, ninety percent (n = 46) of patients percutaneously
biopsied under imaging (CT) guidance had histologic
confirmation of osteosarcoma pre-operatively, with only
four CT-guided core biopsies performed at this institution
requiring an open biopsy for definitive diagnosis of oste-
osarcoma. Improperly performed biopsies, more com-
mon in non-tertiary institutions, are associated with
increased errors in diagnosis, obtaining non-representa-
tive tissue, and adverse outcomes including amputation
and local recurrence [6].
Histologically, osteosarcoma is a malignant spindle-cell
neoplasm that produces osteoid [7]. High-grade osteosar-
coma can be classified into four histologic subtypes (oste-
oblastic, fibroblastic, chondroblastic and telangiectatic)
based on the predominant type of matrix within the
tumour. These subtypes appear to have similar prognoses,
thus rendering the value of these distinctions unclear.
However, tumour grade and identification of two rare
clinical subtypes (parosteal and periosteal osteosarcomas)
appear to be more significant as prognostic indicators,
with these subtypes being associated with a lower risk of
metastasis and more favourable outcome with surgical
resection alone [1,6].
The most widely used staging system is the Enneking sys-
tem, which categorises localised malignant bone tumours
Imaging features of osteosarcoma Figure 4
Imaging features of osteosarcoma. Panel A is a plain radiograph demonstrating a lytic destructive lesion with malignant new 
bone formation involving the medial aspect of left distal femur. Panel B is a coronal CT image showing typical periosteal new 
bone formation with cortical destruction associated with a lytic bony lesion involving the left distal femur. Panel C is an 
enhanced MR image demonstrating an eccentric left distal femoral metaphyseal mass with a large extra-osseous component. 
Panel D is an axial image of a CT-guided biopsy sampling of the extra-osseous mass. Panel E is an image from a thallium bone 
study showing uptake overlying the distal left femur indicative of high grade tumour at this site.
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by grade (low and high grades being Stages 1 and 2,
respectively) and tumour extension through the cortex
(intra-compartmental and extra-compartmental being
classified as subtypes A and B, respectively); patients with
metastatic disease are classified as having Stage 3 disease.
Typically in younger patients, high-grade osteosarcomas
extend through the cortex early in their natural history –
thus, most patients are Stage 2B or 3 at presentation [2].
The differential diagnoses include osteomyelitis, osteosa-
rcoma and other primary bone tumours (myositis ossifi-
cans, aneurysmal bone cyst, Ewing's sarcoma,
chondrosarcoma, giant cell tumour, osteoblastoma,
fibrous dysplasia), and, although infrequent in the paedi-
atric population, metastatic bone disease (lymphoma,
neuroblastoma, rhabdomyosarcoma). The location of the
tumour within the bone and the skeletal location assist in
distinguishing osteosarcoma from Ewing's sarcoma, the
second most frequent type of bone tumour in children
and adolescents.
The management of osteosarcoma is based primarily on
neo-adjuvant and adjuvant chemotherapy and surgical
resection; radiotherapy is not effective as osteosarcomas
are relatively radioresistant. Since 1970, when osteosar-
coma was treated with amputation and/or radiotherapy
and more than eighty percent of patients developed met-
astatic disease following therapy [3,5], advances in chem-
otherapeutic regimens, surgical techniques and radiologic
staging studies have enabled ninety to ninety-five percent
of patients to be treated with limb-sparing resection and
reconstruction. Survival rates of up to sixty percent at five
years [3] and relapse-free rates of sixty to eighty percent [5]
in patients with localised disease at presentation have
been described.
The most consistent prognostic factor at diagnosis is the
presence of clinically detectable metastatic disease [8].
Patients presenting with localised disease have the best
outcome, with a five-year relapse-free survival rate of sixty
to seventy percent [1]. The prognosis of patients with met-
astatic disease at diagnosis is poor and appears to be
related to the number and resectability of pulmonary
nodules, and response to preoperative therapy [1-3]; in
one series the survival rate was only eleven percent despite
intensive chemotherapy [3].
The site of the primary tumour is also of prognostic value,
with axial lesions conferring a poorer outcome, especially
if located in the pelvis [1,2].
The histologic response to neo-adjuvant chemotherapy is
also a consistent prognostic factor, demonstrated either by
magnetic resonance imaging or nuclear scintigraphy prior
to resection, or by histologic analysis of the resection spec-
imen [2,3]. In patients with a good histologic response,
seventy-five percent are relapse-free three years following
therapy [2].
Although patients with recurrent disease generally have a
poor prognosis, this is dependent on the type of therapy
given previously, the duration of remission, and the
extent of metastases [2,3]. With aggressive treatment, the
five-year survival rate in patients with pulmonary meta-
static recurrence may reach forty percent [2], and in
patients with recurrent disease confined to one or a lim-
ited number of pulmonary nodules more than one year
after initial chemotherapy, cure after complete resection
of all nodules is approximately twenty-five percent [1].
The St Vincent's Hospital experience with management of
osteosarcoma compares favourably with published litera-
ture, with over half of our patients (n = 31) remaining
relapse-free during the follow-up period following initial
surgical resection and chemotherapy. Only twelve percent
(n = 7) of patients had localised disease relapse and
twenty-seven percent (n = 16) of patients following initial
curative management subsequently developed distant dis-
ease, the majority (eighty percent) being pulmonary
metastases. Significantly, sixty-two percent (n = 13) of
patients with recurrent disease remained disease-free fol-
lowing subsequent surgical resection(s) within the follow-
up period.
Conclusion
The St Vincent's experience has been comparable to the
published literature in terms of the patient demographics
(age at diagnosis, gender distribution), clinical features
(presenting symptoms, site of tumour) and outcomes
(survival and relapse rates). Through a multidisciplinary
approach in a tertiary referral centre, patient outcomes
may be optimised. Use of multiple imaging modalities,
including CT-guided biopsy, to demonstrate typical radi-
ographic and histopathologic features of osteosarcoma
facilitates surgical planning and appropriate use of neo-
adjuvant chemotherapy. Follow-up is essential following
initial therapy, as patients may relapse with metastatic dis-
ease, most commonly to the lungs, which may be treata-
ble with surgery and chemotherapy.
Abbreviations
CT computed tomography
MR magnetic resonance
PET positron emission tomography
Competing interests
The author(s) declare that they have no competing inter-
ests.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
International Seminars in Surgical Oncology 2006, 3:38 http://www.issoonline.com/content/3/1/38
Page 8 of 8
(page number not for citation purposes)
Authors' contributions
J. Z-Y Tan participated in the study design, collated the
data, performed the statistical analysis and drafted the
manuscript.
S. M. Schlicht conceived the study, participated in the
study design, helped draft the manuscript, carried out the
percutaneous bone biopsies and reviewed the imaging
studies.
G. J. Powell and P. F. M. Choong performed the surgical
procedures and obtained pathology samples.
D. Thomas provided medical oncology expertise regard-
ing neo-adjuvant and adjuvant chemotherapy regimens.
J. L. Slavin reviewed the histopathology.
P. J. Smith reviewed the imaging studies.
All authors read and approved the final manuscript.
Acknowledgements
We are indebted to Ie-Wen Sim, M.B.B.S, B.Med.Sci, for his critical review 
of the manuscript and helpful suggestions.
References
1. Arndt CAS, Crist WM: Medical Progress: Common Muscu-
loskeletal Tumors of Childhood and Adolescence.  New Eng-
land Journal of Medicine 1999, 341:342-352.
2. Marina N, Gebhardt M, Teot L, Gorlick R: Biology and Therapeu-
tic Advances for Pediatric Osteosarcoma.  The Oncologist 2004,
9:422-441.
3. Pierz KA, Womer RB, Dormans JP: Pediatric Bone Tumors:
Osteosarcoma, Ewing's Sarcoma, and Chondrosarcoma
Associated With Multiple Hereditary Osteochondromato-
sis.  Journal of Pediatric Orthopaedics 2001, 21:412-418.
4. Sturgis EM, Potter BO: Sarcomas of the head and neck region.
Current Opinion in Oncology 2003, 15:239-252.
5. Wittig JC, Bickels J, Priebat D, Jelinek J, Kellar-Graney K, Shmookler
B, Malawer MM: Osteosarcoma: A Multidisciplinary Approach
to Diagnosis and Treatment.  American Family Physician 2002,
65:1123-1132.
6. Bramwell VHC: Osteosarcomas and other cancers of bone.
Current Opinion in Oncology 2000, 12:330-336.
7. Di Caprio MR, Lindskog DM, Husted D, Reith J, Scarborough MT:
Knee Pain in a 14-Year-Old Girl.  Clinical Orthopaedics and Related
Research 2005, 435:267-275.
8. Hoffer FA: Primary Skeletal Neoplasms: Osteosarcoma and
Ewing Sarcoma.  Topics in Magnetic Resonance Imaging 2002,
13:231-240.
9. Hawkins DS, Rajendran JG, Conrad 3rd EU, Bruckner JD, Eary JF:
Evaluation of chemotherapy response in pediatric bone sar-
comas by [F-18]-fluorodeoxy-D-glucose positron emission
tomography.  Cancer 2002, 94:3277-3284.
10. Huang TL, Liu RS, Chen TH, Chen WY, Hsu HC, Hsu YC: Compar-
ison between F-18-FDG positron emission tomography and
histology for the assessment of tumor necrosis rates in pri-
mary osteosarcoma.  Journal of Chinese Medicine Association 2006,
69:372-376.
11. Schulte M, Brecht-Krauss D, Werner M, Hartwig E, Sarkar MR, Kep-
pler P, Kotzerke J, Guhlmann A, Delling G, Reske SN: Evaluation of
neoadjuvant therapy response of osteosarcoma using FDG
PET.  Journal of Nuclear Medicine 1999, 40:1637-1643.
12. Franzius C, Sciuk J, Brinkschmidt C, Jurgens H, Schober O: Evalua-
tion of chemotherapy response in primary bone tumors with
F-18 FDG positron emission tomography compared with his-
tologically assessed tumor necrosis.  Clinical Nuclear Medicine
2000, 25:874-881.
13. Franzius C, Sciuk J, Daldrup-Link HE, Jurgens H, Schober O: FDG-
PET for detection of osseous metastases from malignant pri-
mary bone tumours: comparison with bone scintigraphy.
European Journal of Nuclear Medicine 2000, 27:1305-1311.
14. Franzius C, Daldrup-Link HE, Sciuk J, Rummeny EJ, Bielack S, Jurgens
H, Schober O: FDG-PET for detection of pulmonary metas-
tases from malignant primary bone tumours: comparison
with spiral CT.  Annals of Oncology 2001, 12:479-486.